CORCEPT THERAPEUTICS INC — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Sean Maduck, former President of Corcept Endocrinology, transitioned to independent consultant effective October 1, 2026, at $57,000/month with continued stock option vesting. Roberto Vieira (President, Oncology; hired January 2024 at $527,000 base + 50% bonus + 400,000 options) and Justin Gunn (VP National Sales; hired July 2024 at $435,000 base + 35% bonus + 50,000 options) each received severance and change-of-control agreements providing 12 months base salary, COBRA coverage, and full equity acceleration upon termination within 18 months of a change in control.
Why this rating
Routine executive employment/severance documentation. Total annual consulting/salary commitments (~$2M) and option grants (~450,000 shares) are modest relative to $6.1B market cap. No material business event disclosed.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.